Key facts
- Alleviant Medical’s last known valuation is $260.0M (Dec 2024).
- It has raised $189.1M across 4 recorded rounds; the latest was Later Stage VC ($90.8M) in Dec 2024.
- Notable investors include MassChallenge, MedTech Innovator, Texas Medical Center, Johnson & Johnson Innovation - JLABS, S3 Ventures — 17 tracked in total.
- Alleviant Medical has filed 5 Form Ds with the SEC since 2018, most recently Jan 2025 ($90.8M sold to 12 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 17 names
- ·Watchlist + deal alerts for Alleviant Medical
Funding rounds
4 roundsAbout Alleviant Medical
Developer of medical devices designed to offer treatment for congestive heart failure. The company's devices relieve pressure buildup in the left atrium of the heart that can lead to organ failures and is developing next-generation therapies for heart failure, enabling hospitals to provide symptomatic relief and appropriate treatments to patients.
- Sector
- Healthcare
- HQ
- Austin, TX, United States
- Founded
- 2017
- Employees
- 44
- Website
- alleviantmedical.com/
- Ownership
- Privately Held (backing)
Alleviant Medical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Alleviant Medical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Alleviant Medical in its N-PORT filings yet. We sweep new filings monthly.